Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Naproxen × Gastrointestinal × Clear all
NCT05411718 2026-06-01

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02052908 2021-01-25

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
81 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡